About Us

About Respirogen

Respirogen Inc., based in Boulder, Colorado, is a pioneering company specializing in oxygen microbubble technology. With a focus on research collaboration, technology licensing, and business development, Respirogen offers innovative solutions for various clinical applications.

Driven by a team of experts, Respirogen is dedicated to advancing the field of oxygen microbubble markets, providing cutting-edge solutions that have the potential to revolutionize respiratory therapies and improve patient outcomes. Respirogen's technology will provide oxygen independent from damaged lungs. Acute respiratory distress syndrome (ARDS) is an acute severe lung disease commonly encountered in intensive care units (ICU). It can be caused by several triggers, including pneumonia or trauma. It is characterized by widespread injury of the alveolar–capillary membrane, resulting in protein rich noncardiogenic pulmonary edema (fluid accumulation in the lungs) and acute respiratory failure (ARF). ARDS results in severe hypoxaemia, which is refractory to oxygen treatment and requires assisted ventilation.

Research Opportunities

Multiple additional research opportunities have been identified for development of OMB therapies: 

• Expanded lung compromise indications including smoke/chemical inhalation, pediatric respiratory distress and surfactant therapy, and extension of safe apnea during intubation 
• Field oxygenation for emergency medical transport including battlefield injuries 
• Reducing local hypoxia in tumor tissue to prevent vascularization which leads to tumor growth 
• Consumer products including over the counter cosmetics and wound healing